Cargando…

Impact of residual tumor cells in the stem cell collection on multiple myeloma patients receiving autologous stem cell transplantation

Autologous stem cell transplantation (ASCT) is the standard therapy for patients with transplant-eligible multiple myeloma (TEMM). However, the ideal depth of response required before ASCT and the impact of residual tumor cells in the stem cell collection (SCC) on survival remains unclear. Here we c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Jingyu, Yan, Wenqiang, Fan, Huishou, Liu, Jiahui, Li, Lingna, Du, Chenxing, Deng, Shuhui, Sui, Weiwei, Xu, Yan, Qiu, Lugui, An, Gang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10567849/ https://www.ncbi.nlm.nih.gov/pubmed/37679605 http://dx.doi.org/10.1007/s00277-023-05427-8

Ejemplares similares

P910: DOES MINIMAL RESIDUAL DISEASE OF STEM CELL COLLECTION HAVE PROGNOSTIC IMPACT ON PATIENTS WITH MULTIPLE MYELOMA?
por: Jingyu, X., et al.
Publicado: (2022)

Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
por: Liu, Jiahui, et al.
Publicado: (2023)

Prognostic value of the Second Revision of the International Staging System (R2-ISS) in a real-world cohort of patients with newly-diagnosed multiple myeloma
por: Yan, Wenqiang, et al.
Publicado: (2023)

PB2005: BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: A REAL-WORLD STUDY OF CHINA
por: Jingyu, X., et al.
Publicado: (2022)

P935: EARLY RELAPSE WITHIN 18 MONTHS (ER18) IS A POWERFUL DYNAMIC PREDICTOR FOR PROGNOSIS AND COULD REVISE STATIC RISK DISTRIBUTION IN PATIENTS WITH NEWLY-DIAGNOSED MULTIPLE MYELOMA
por: Yan, Wenqiang, et al.
Publicado: (2023)

Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISH
por: Yan, Yuting, et al.
Publicado: (2022)

P844: GLOBAL CHARACTERIZATION OF MONOCYTE REVEALS A STRESS SIGNATURE INDUCED BY MULTIPLE MYELOMA BY SINGLE-CELL RNA SEQUENCING
por: Cui, Jian, et al.
Publicado: (2023)

Autologous Stem Cell Transplantation for Myeloma: Cytoreduction or an Immunotherapy?
por: Minnie, Simone A., et al.
Publicado: (2021)

P806: TRACKING THE CLONAL EVOLUTION AND DRUG RESISTANCE PATHWAY OF NEWLY DIAGNOSED MULTIPLE MYELOMA THROUGH SINGLE-CELL RNA SEQUENCING
por: Cui, Jian, et al.
Publicado: (2023)

Autologous Stem Cell Transplantation in Multiple Myeloma with Renal Failure: Friend or Foe?
por: Zhong, Hongfei, et al.
Publicado: (2019)

Current status of autologous stem cell transplantation for multiple myeloma
por: Al Hamed, Rama, et al.
Publicado: (2019)

Pharmacokinetic‐Pharmacodynamic Model of Neutropenia in Patients With Myeloma Receiving High‐Dose Melphalan for Autologous Stem Cell Transplant
por: Cho, Yu Kyoung, et al.
Publicado: (2018)

Treatment Pattern and Outcomes in Newly Diagnosed Multiple Myeloma Patients Who Did Not Receive Autologous Stem Cell Transplantation: A Real-World Observational Study: Treatment pattern and outcomes in patients with multiple myeloma
por: He, Jianming, et al.
Publicado: (2020)

Targeting stem cell niche can protect hematopoietic stem cells from chemotherapy and G-CSF treatment
por: Li, Sidan, et al.
Publicado: (2015)

Detection of Minimal Residual Disease by Flow Cytometry for Patients with Multiple Myeloma Submitted to Autologous Hematopoietic Stem Cell Transplantation
por: Dal Bó, Suzane, et al.
Publicado: (2013)

Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma without Cryopreservation
por: Al-Anazi, Khalid Ahmed
Publicado: (2012)

Update on the Role of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
por: Tosi, P., et al.
Publicado: (2012)

Complete response after autologous stem cell transplant in multiple myeloma
por: Kumar, Lalit, et al.
Publicado: (2014)

Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma
por: Al-Mansour, Zeina, et al.
Publicado: (2014)

Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma
por: Paquin, Ashley, et al.
Publicado: (2020)

Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
por: Yarlagadda, Lakshmi, et al.
Publicado: (2021)

Interrupted Identities: Autologous Stem Cell Transplant in Patients With Multiple Myeloma
por: Halpin, Sean N, et al.
Publicado: (2021)

Outcomes of autologous stem cell transplantation for multiple myeloma in Saudi Arabia
por: Abdrabou, Ahmed Kotb, et al.
Publicado: (2021)

Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma
por: Srour, Samer A., et al.
Publicado: (2021)

Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells
por: Hao, Mu, et al.
Publicado: (2011)

Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma
por: Nahi, Hareth, et al.
Publicado: (2022)

MicroRNA-15a/16-1 cluster located at chromosome 13q14 is down-regulated but displays different expression pattern and prognostic significance in multiple myeloma
por: Li, Fei, et al.
Publicado: (2015)

The influence of high-efficiency particulate air filtration on mortality among multiple myeloma patients receiving autologous stem cell transplantation
por: Tsai, Chun-Kuang, et al.
Publicado: (2021)

Immunotherapy for multiple myeloma: new chances and hope
por: Xu, Jingyu, et al.
Publicado: (2023)

Lenalidomide before and after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
por: Tuchman, S. A., et al.
Publicado: (2012)

Therapeutic effects of autologous hematopoietic stem cell transplantation in multiple myeloma patients
por: FU, CHENGCHENG, et al.
Publicado: (2013)

Comparison of single and double autologous stem cell transplantation in multiple myeloma patients
por: Malkan, Umit Yavuz, et al.
Publicado: (2021)

Long-Term Responders After Autologous Stem Cell Transplantation in Multiple Myeloma
por: Oliver-Caldes, Aina, et al.
Publicado: (2022)

Experience of Autologous Stem Cell Transplant in Multiple Myeloma: The Patient and Caregiver Perspective
por: Hansen, Doris K, et al.
Publicado: (2023)

High levels of circulating CD34+ cells at autologous stem cell collection are associated with favourable prognosis in multiple myeloma
por: Raschle, J, et al.
Publicado: (2011)

Outcomes of Non-Cryopreserved Versus Cryopreserved Peripheral Blood Stem Cells for Autologous Stem Cell Transplantation in Multiple Myeloma
por: Piriyakhuntorn, Pokpong, et al.
Publicado: (2020)

Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study
por: Derman, Benjamin A, et al.
Publicado: (2020)

Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation
por: Takamatsu, H., et al.
Publicado: (2017)

Successful autologous stem cell collection with filgrastim and plerixafor after long-term lenalidomide therapy for multiple myeloma
por: Agarwal, Rishi, et al.
Publicado: (2012)

Non-Cryopreserved Peripheral Blood Stem Cell Graft for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma and Lymphoma Patients
por: Noiperm, Panarat, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_uekge9nu55l5hnugdajbuhr3ru